Key Findings
The Europe antihypertensive drugs market is estimated to grow with an anticipated CAGR of 2.70% during the forecast years of 2019 to 2028. The region also accounted for harboring the second-largest market share in terms of revenue, in 2019.

Market Insights
Countries included for analyzing the Europe antihypertensive drugs market growth are France, Germany, Russia, Belgium, the United Kingdom, Italy, Poland, and the rest of Europe. The presence of key players like Novartis AG, Sanofi, and AstraZeneca Plc, ensure easy availability of antihypertensive drugs in the region. Moreover, an increased prevalence of a vast patient base suffering from hypertension drives market growth. In Germany, increasing healthcare expenses and a rise in aging residents have been beneficial for the antihypertensive drugs market growth. The incidence of chronic disorders like blood pressure, asthma, and diabetes, among others, has resulted in the majority of deaths in the country. This is likely to promote Germany’s antihypertensive drugs market growth. According to the latest projections by the United Nations, Italy’s population in 2019 was estimated at 60.55 million. In the same year, 29.4% of the country’s population was over 60 years old. This figure is expected to rise to a massively by 2050. In Italy, over 24 million people suffered from chronic disorders in 2018. Therefore, the increase in the geriatric population, along with a rise in chronic diseases, is predicted to fuel the market growth. Poland’s market growth is expected to be propelled by the mortality rate due to chronic obstructive pulmonary disease (COPD) as well as the upsurge in aging individuals.

Competitive Insights
Some of the notable companies in the market are Medtronic Plc, Daiichi Sankyo Company Limited, Novartis AG, Boehringer Ingelheim International GmbH, Pfizer Inc, etc.
Our report offerings include:

  • Explore key findings of the overall market
  • Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
  • Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
  • Market Segmentation cater to a thorough assessment of key segments with their market estimations
  • Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
  • Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
  • Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
  • Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments